# Gaxos.Ai Inc.: financial statements, quarterly

GXAI · Nasdaq · CIK 1895618 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gxai.md) · [Financials](/companies/gxai/financials.md) · [Filings](/companies/gxai/filings.md) · [Insiders](/companies/gxai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gxai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [0.0](/filings/0001213900-25-044276.md) | [0.0 d](/filings/0001213900-25-075633.md) | [2.7](/filings/0001213900-25-110000.md) | [1.3 d](/filings/0001213900-26-029223.md) | [23.7](/filings/0001213900-26-056583.md) | [171](/filings/0001213900-26-088350.md) | [498](/filings/0001213900-25-110000.md) | [1,240 d](/filings/0001213900-26-029223.md) | [1,809](/filings/0001213900-26-056583.md) | [2,457](/filings/0001213900-26-088350.md) |
| Research and development | $k | [258](/filings/0001213900-24-098442.md) | [285 d](/filings/0001013762-25-004271.md) | [182](/filings/0001213900-25-044276.md) | [249](/filings/0001213900-25-075633.md) | [253](/filings/0001213900-25-110000.md) | [312 d](/filings/0001213900-26-029223.md) | [221](/filings/0001213900-26-056583.md) | [243](/filings/0001213900-26-088350.md) | [274](/filings/0001213900-25-110000.md) | [256 d](/filings/0001213900-26-029223.md) | [446](/filings/0001213900-26-056583.md) | [507](/filings/0001213900-26-088350.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(874)](/filings/0001213900-24-098442.md) | [(831) d](/filings/0001013762-25-004271.md) | [(1,044)](/filings/0001213900-25-044276.md) | [(855)](/filings/0001213900-25-075633.md) | [(906)](/filings/0001213900-25-110000.md) | [(899) d](/filings/0001213900-26-029223.md) | [(1,392)](/filings/0001213900-26-056583.md) | [(983)](/filings/0001213900-26-088350.md) | [(1,315)](/filings/0001213900-25-110000.md) | [(1,227) d](/filings/0001213900-26-029223.md) | [(2,547)](/filings/0001213900-26-056583.md) | [(1,865)](/filings/0001213900-26-088350.md) |
| Net income | $k | [(857)](/filings/0001213900-24-098442.md) | [(801) d](/filings/0001013762-25-004271.md) | [(912)](/filings/0001213900-25-044276.md) | [(809)](/filings/0001213900-25-075633.md) | [(864)](/filings/0001213900-25-110000.md) | [(832) d](/filings/0001213900-26-029223.md) | [(1,192)](/filings/0001213900-26-056583.md) | [(749)](/filings/0001213900-26-088350.md) | [(1,001)](/filings/0001213900-25-110000.md) | [(958) d](/filings/0001213900-26-029223.md) | [(2,173)](/filings/0001213900-26-056583.md) | [241](/filings/0001213900-26-088350.md) |
| Diluted EPS | $ per share | [(0.85)](/filings/0001213900-24-098442.md) | not reported | [(0.91)](/filings/0001213900-25-044276.md) | [(0.72)](/filings/0001213900-25-075633.md) | [(0.61)](/filings/0001213900-25-110000.md) | not reported | [(0.17)](/filings/0001213900-26-056583.md) | [(0.11)](/filings/0001213900-26-088350.md) | [(0.14)](/filings/0001213900-25-110000.md) | not reported | [(0.25)](/filings/0001213900-26-056583.md) | [0.02](/filings/0001213900-26-088350.md) |
| Basic EPS | $ per share | [(0.85)](/filings/0001213900-24-098442.md) | not reported | [(0.91)](/filings/0001213900-25-044276.md) | [(0.72)](/filings/0001213900-25-075633.md) | [(0.61)](/filings/0001213900-25-110000.md) | not reported | [(0.17)](/filings/0001213900-26-056583.md) | [(0.11)](/filings/0001213900-26-088350.md) | [(0.14)](/filings/0001213900-25-110000.md) | not reported | [(0.25)](/filings/0001213900-26-056583.md) | [0.02](/filings/0001213900-26-088350.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.8](/filings/0001213900-23-086878.md) | [1.0](/filings/0001213900-24-068298.md) | [3.3](/filings/0001213900-24-042974.md) | [2.4](/filings/0001213900-24-068298.md) | not reported | [14.4](/filings/0001213900-26-029223.md) | [2.6](/filings/0001213900-25-044276.md) | [1.7](/filings/0001213900-25-075633.md) | [0.9](/filings/0001213900-25-110000.md) | [0.8](/filings/0001213900-26-029223.md) | [1.5](/filings/0001213900-26-056583.md) | [1.1](/filings/0001213900-26-088350.md) |
| Current assets | $m | [4.4](/filings/0001213900-23-086878.md) | [3.6](/filings/0001013762-25-004271.md) | [5.8](/filings/0001213900-24-042974.md) | [4.9](/filings/0001213900-24-068298.md) | [6.9](/filings/0001213900-24-098442.md) | [16.8](/filings/0001213900-26-029223.md) | [15.2](/filings/0001213900-25-044276.md) | [14.5](/filings/0001213900-25-075633.md) | [13.4](/filings/0001213900-25-110000.md) | [12.6](/filings/0001213900-26-088350.md) | [12.2](/filings/0001213900-26-056583.md) | [11.9](/filings/0001213900-26-088350.md) |
| Total assets | $m | [4.4](/filings/0001213900-23-086878.md) | [3.7](/filings/0001013762-25-004271.md) | [6.0](/filings/0001213900-24-042974.md) | [5.1](/filings/0001213900-24-068298.md) | [7.1](/filings/0001213900-24-098442.md) | [17.0](/filings/0001213900-26-029223.md) | [16.1](/filings/0001213900-25-044276.md) | [15.4](/filings/0001213900-25-075633.md) | [14.3](/filings/0001213900-25-110000.md) | [13.4](/filings/0001213900-26-088350.md) | [15.8](/filings/0001213900-26-056583.md) | [17.5](/filings/0001213900-26-088350.md) |
| Current liabilities | $m | [0.2](/filings/0001213900-23-086878.md) | [0.3](/filings/0001013762-25-004271.md) | [0.5](/filings/0001213900-24-042974.md) | [0.4](/filings/0001213900-24-068298.md) | [0.4](/filings/0001213900-24-098442.md) | [0.4](/filings/0001213900-26-029223.md) | [0.5](/filings/0001213900-25-044276.md) | [0.5](/filings/0001213900-25-075633.md) | [0.5](/filings/0001213900-25-110000.md) | [0.7](/filings/0001213900-26-088350.md) | [0.6](/filings/0001213900-26-056583.md) | [1.1](/filings/0001213900-26-088350.md) |
| Total liabilities | $m | [0.2](/filings/0001213900-23-086878.md) | [0.3](/filings/0001013762-25-004271.md) | [0.5](/filings/0001213900-24-042974.md) | [0.4](/filings/0001213900-24-068298.md) | [0.4](/filings/0001213900-24-098442.md) | [0.4](/filings/0001213900-26-029223.md) | [0.5](/filings/0001213900-25-044276.md) | [0.5](/filings/0001213900-25-075633.md) | [0.5](/filings/0001213900-25-110000.md) | [0.7](/filings/0001213900-26-088350.md) | [0.6](/filings/0001213900-26-056583.md) | [1.1](/filings/0001213900-26-088350.md) |
| Shareholders' equity | $m | [4.2](/filings/0001213900-24-098442.md) | [3.4](/filings/0001013762-25-004271.md) | [5.5](/filings/0001213900-24-098442.md) | [4.7](/filings/0001213900-24-098442.md) | [6.7](/filings/0001213900-24-098442.md) | [16.6](/filings/0001213900-26-029223.md) | [15.6](/filings/0001213900-25-044276.md) | [15.0](/filings/0001213900-25-075633.md) | [14.1](/filings/0001213900-25-110000.md) | [13.1](/filings/0001213900-26-088350.md) | [15.9](/filings/0001213900-26-056583.md) | [17.3](/filings/0001213900-26-088350.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(874) d](/filings/0001213900-24-098442.md) | [(673) d](/filings/0001013762-25-004271.md) | [(1,099)](/filings/0001213900-25-044276.md) | [(738) d](/filings/0001213900-25-075633.md) | [(674) d](/filings/0001213900-25-110000.md) | [(768) d](/filings/0001213900-26-029223.md) | [(1,297)](/filings/0001213900-26-056583.md) | [(717) d](/filings/0001213900-26-088350.md) | [(1,106) d](/filings/0001213900-25-110000.md) | [(733) d](/filings/0001213900-26-029223.md) | [(2,494)](/filings/0001213900-26-056583.md) | [(1,088) d](/filings/0001213900-26-088350.md) |
| Share repurchases | $k | [25.5 d](/filings/0001213900-24-098442.md) | [50.0 d](/filings/0001213900-24-026681.md) | [19.6](/filings/0001213900-24-042974.md) | [0.0 d](/filings/0001213900-24-068298.md) | [0.0 d](/filings/0001213900-24-098442.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.4](/filings/0001213900-23-086878.md) | [0.9](/filings/0001213900-24-042974.md) | [1.0](/filings/0001213900-24-068298.md) | [1.0](/filings/0001213900-24-098442.md) | [1.0](/filings/0001213900-25-044276.md) | [1.1](/filings/0001213900-25-075633.md) | [1.4](/filings/0001213900-25-110000.md) | [7.0](/filings/0001213900-26-056583.md) | [7.1](/filings/0001213900-26-088350.md) | [7.1](/filings/0001213900-25-110000.md) | [8.6](/filings/0001213900-26-056583.md) | [10.4](/filings/0001213900-26-088350.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,744,634 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001213900-26-088350.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.